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With an incidence that is increasing at 2–5% per year, cutaneous melanoma is an international scourge that disproportionately
targetsyoungindividuals.Despitemuchresearch,thetreatmentofadvanceddiseaseisstillquitechallenging.Immunotherapywith
high-dose interferon-α2b or interleukin-2 beneﬁts a select group of patients in the adjuvant and metastatic settings, respectively,
with signiﬁcant attendant toxicity. Advances in the biology of malignant melanoma and the role of immunomodulatory therapy
have produced advances that have stunned the ﬁeld. In this paper, we review the data for the use of interferon-α2b in various
dosing ranges, vaccine therapy, and the role of radiotherapy in the adjuvant setting for malignant melanoma. Recent trials in
the metastatic setting using anticytoxic T-lymphocyte antigen-4 (anti-CTLA-4) monoclonal antibody therapy and BRAF inhibitor
therapy have demonstrated clear beneﬁt with prolongation of survival. Trials investigating combinations of these novel agents with
existing immunomodulators are at present underway.
1.Introduction
The therapeutic armamentarium for melanoma has ex-
panded recently to include several promising agents. How-
ever, there remains a signiﬁcant fraction of patients with
advanceddiseaseforwhomtreatmentoptionsareunsuccess-
ful. The incidence of melanoma has increased steadily over
theyears(currentlyrepresentingtheﬁfthmostcommoncan-
cerinmenandtheseventhmostcommoncancerinwomen),
increasing at a rate greater than any other human cancer.
Melanoma remains a deadly disease that disproportionately
targets young individuals in their prime, taking a societal toll
that is greater than many other more common malignancies,
such as prostate carcinoma.
For patients with surgically resected melanoma of a
primary tumor thickness of 4mm or greater (T4 lesions)
and/or regional lymph node metastases who are at increased
risk of recurrence and death (stages IIB or greater), the
only Federal Drug Administration (FDA) approved eﬀective
adjuvant therapy remains interferon-α (IFN-α).
The standard therapy for patients with metastatic disease
has been dacarbazine. Its oral analogue temozolomide has
shown equivalent beneﬁt, but has not been approved by the
FDA for treatment of melanoma. [1, 2] Response rates with
dacarbazine have consistently been less than 10% in recent
randomizedcontrolledtrialsandaregenerallytransient.This
hitherto stagnant ﬁeld has seen the advent of two promising
new agents that oﬀer much hope to patients and physi-
cians alike. Ipilimumab (MDX-010, Yervoy), a fully human
monoclonal antibody (IgG1) that blocks the T-cell surface
protein CTLA-4 that has immunoregulatory functions, has
demonstrated a survival advantage for ipilimumab given at
3mg/kg every 3 weeks × 4 against a vaccine comparator
for second-line therapy that led to fast-track approval
from the FDA for treatment of metastatic melanoma [3].
The recent presentation of data from the phase III ﬁrst-
line trial of ipilimumab given with dacarbazine compared
against dacarbazine alone has conﬁrmed the beneﬁt of
ipilimumab with improved response, progression free and
overallsurvival,andwithanincrementof10%inthefraction
of patients surviving at 2-3 years that is similar to the results
of the second-line trial MDX 10–20 that was published in
2010. These data have led to FDA approval of ipilimumab
in March of 2011 [4]. The BRIM 3 study published in June
2011[5]hasdemonstratedaprogressionfreeandoverallsur-
vival advantage for treatment with vemurafenib (Zelboraf)
compared to dacarbazine—this inhibitor of the oncogenic
BRAF kinase received FDA approval in August 2011. Other2 Journal of Skin Cancer
treatment options in the metastatic disease setting include
high-dose interleukin 2 (IL-2), which achieves durable long-
term complete responses in a small proportion of patients
treated but has yet to be formally compared to dacarbazine
in a randomized phase III study.
Various combinations of biological agents and chemo-
therapy (“biochemotherapy”) have been tested in phases
II and III settings. Several have demonstrated increases in
objective response rates at initial single institution phase II
evaluation, but none have demonstrated survival beneﬁt in
randomized phase III trials [6].
This review paper will focus on recently published
advances on the adjuvant treatment of high-risk melanoma.
It will update the data since prior reviews published in 2010
[7, 8] and include discussion of several recent meta-analyses
[9–12].
2.MaterialsandMethods
2.1. Search Strategy and Selection Criteria. As y s t e m a t i c
search strategy was utilized to interrogate the Medline,
Embase, Cancerlit, Cochrane, ISI, and Web of Science
databases for articles published between January 1, 2002 and
February1,2011.MeSHheadingsusedincluded“melanoma,
advanced,” “melanoma, adjuvant,” or “melanoma, inter-
feron” for trials conducted in the adjuvant setting. Searches
were limited to clinical trials and publications in English
or with available English translations. The “related articles”
feature of PubMed was used for all reports that met the
requested criteria as an additional means of identifying
potentially relevant investigations. Data from recently pub-
lished and ongoing phase I/II/III trials were gathered by
searching clinical trial databases. The abstract databases of
the American Society of Clinical Oncology (ASCO) and
European Society for Medical Oncology annual congresses
were also searched for recently released clinical trial data.
Additionally, the references in reviewed articles were ana-
lyzed to ﬁnd further relevant publications.
3. Discussion
3.1. Indications for Adjuvant Therapy. Adjuvant therapy has
traditionally been reserved for those postoperative patients
at high risk of developing advanced disease. Research has
attempted to deﬁne the clinical and pathologic features that
predict risk of relapse, metastasis, and overall survival (OS).
Currently, adjuvant therapy with high-dose IFN alfa-2b is
the standard of care for patients with resected node-positive
melanoma (stage III) and should be considered for patients
with node-negative disease with a high risk of recurrence,
that is, deep primary tumors (T3b, T4 a/b) whose estimated
risk of recurrence exceeds 30% [13].
3.2. Clinical Predictive Factors. Five factors have demon-
strated independent predictive value in relation to relapse
and mortality based on observations of patients in the 2008
American Joint Committee on Cancer (AJCC) Melanoma
Staging Database. These ﬁndings were incorporated into
the revised 2009 classiﬁcation on the staging and prognosis
of cutaneous melanoma copublished by the AJCC and the
International Union against Cancer (UICC).
Thesinglemostimportantfactorforlocalizedmelanoma
isthedepthoftheprimarytumor (Breslow’stumorthickness).
As tumor thickness increases, the 5- and 10-year survival
rates decline. While 10-year survival is 92% among patients
with T1 primary lesions and 80% among patients with T2
lesions, it drops to 63% in patients with T3 melanomas (2.01
to 4.00mm thick) and further falls to 50% in patients with
T4 tumors that are more than 4.00mm thick.
The presence of primary tumor ulceration (deﬁned as the
absence of intact epidermis overlying a signiﬁcant portion
of melanoma in microscopic analysis) is well known to
adversely aﬀect survival. Survival rates of patients with an
ulcerated melanoma are proportionately lower than those
of patients with a nonulcerated melanoma of equivalent T
category but are very similar to patients with a nonulcerated
melanoma of the next highest T category. The presence of
primary tumor ulceration upstages each T category and is
designatedbytheadditionof“b”inconjunctionwiththeT1-
4 classiﬁcation. As an example, T2b, ulcerated melanomas
(1-2mm in thickness) have a 5-year survival of 82%, while
the survival for the deeper T3a category without ulceration
is 79%—and both are grouped in the stage IIA category
accordingly.
Analysis of the AJCC Melanoma Staging Database data
demonstrated that the mitotic rate was the second most
powerful predictor of survival for localized melanoma after
tumor thickness. Increasing mitotic rate (at least one mitosis
persquaremillimeter) isstronglycorrelatedwithdiminished
survival rates and is now a component of the 7th edition
melanoma staging system. It has also replaced the Clark
level of invasion as a primary criterion for deﬁning T1b
melanoma—which is now deﬁned as those lesions whose
tumor thickness is ≤1.0mm containing at least one mitosis
per square millimeter regardless of tumor ulceration.
Regional metastases clinically evident as lymphadenopa-
thy or intralymphatic (satellite or in-transit) metastasis are
importantpredictorsofoutcome.The7theditionAJCCstag-
ing system abolished the concept of a minimum threshold of
lymphatic tumor burden deﬁning the presence of regional
nodal metastases. Speciﬁcally, lymph node tumors of less
than 0.2mm that were previously ignored in staging nodal
disease were felt to be biologically and clinically signiﬁcant
and were now included in deﬁnition of nodal disease. This
measure, coupled with the criterion that nodal micrometas-
tases could be deﬁned by immunohistochemical staining
rather than by H&E alone, underscored the importance of
microscopic involvement of lymph nodes rather than the
size of nodal involvement in predicting survival. This is best
illustrated by the 5-year survival of stage III patients, which
subdivided according to extent of lymph node involvement
show a steady decline from 78% to 59%, and 40% for stages
IIIA, IIIB, and IIIC, respectively.
For systemic metastatic disease, the number of metastatic
sites, the sites of distant metastases, and the serum lactate
dehydrogenase (LDH) enzyme level are important prognostic
factors. Elevated LDH levels are known to herald a moreJournal of Skin Cancer 3
malignant phenotype of the disease, and its importance in
this regard is reﬂected in the M1c designation (includes
nonlung visceral metastases) of the 7th edition AJCC staging
system. One-year survival of patients with M1c disease is
33%, as compared to 62% for M1a melanomas (distant
skin, subcutaneous, and lymph node metastases) and 53%
for M1b melanomas (lung metastases). Recent work using
immunohistochemical analysis of LDH expression in tissues
of nevi and melanomas has shown that LDH expression
is closely related to the progression of melanomas—being
barely detectable in nevi but strongly expressed in thick
primary melanoma and in metastatic melanoma [14].
3.3. IFN Therapy. An English virologist (Isaacs) and a Swiss
researcher (Lindenmann) discovered IFN after noticing that
heat-inactivated inﬂuenza virus inhibited the growth of live
inﬂuenza virus in vitro in 1957.
In the next two decades, multiple experiments suggested
that interferons had antitumor eﬀects in a broad range of
laboratory models. Following the puriﬁcation of interferons
and the subsequent cloning of interferon genes in the 1980s,
itbecameclearthatfarfrombeingasinglemolecularspecies,
interferons comprise a large family of structurally related
molecules with diverse biological eﬀects. Once the interferon
gene was inserted into bacteria using recombinant DNA
technology [15], it was a mere matter of time before the
commercial applications of interferon were discovered.
IFNs are subclassiﬁed as types I and II according to their
structural and functional properties. Type II IFNs (IFN-γ in
humans) are released by Th1 cells. Signaling via the IFN-
γ receptor (IFN-γR), IFN-γ recruits leukocytes to infected
areas resulting in inﬂammation, stimulates macrophages
to phagocytose engulfed bacteria, and upregulates the Th2
response. Type I IFNs comprise a number of structurally
similar molecules that all signal via the IFN-α receptor (IFN-
αR). Whilst several subtypes have been identiﬁed, IFN-α,
IFN-β,a n dI F N - ω are the most important ones in humans.
Type I IFNs are produced in large quantities chieﬂy by
the plasmacytoid dendritic cell in response to infectious
and other noxious stimuli. Connecting the adaptive and
innate arms of the immune response, type 1 IFNs have
potent immunoregulatory, antiproliferative, diﬀerentiation-
inducing, apoptotic, and antiangiogenic properties.
3.3.1.IFNTherapy:Mechanism. Themechanism(s)bywhich
IFNsexertantitumoreﬀectsinmelanomaisnotfullyknown.
Evidence from both animal and human studies suggests that
the eﬀects of IFN-α are secondary to immunomodulatory
eﬀectsratherthandirectcytotoxicmechanisms.Inatrialthat
tested neoadjuvant high-dose interferon (HDI) given prior
to deﬁnitive lymph node dissection for patients with stage
IIIB/C disease, investigators demonstrated that HDI resulted
in a brisk inﬂux of T lymphocytes and dendritic cells into
the tumor in a fashion that directly correlated with response
rates [16].
Subsequent analysis showed that HDI downregulates
the MEK/ERK MAPK pathway that plays a role in tumor
cell metastasis [17]. In addition, interferon also appears
to downregulate STAT3—a critical progression marker in
cancer cell survival, proliferation, angiogenesis, metastasis,
and immune evasion [18, 19].
3.3.2. IFN Therapy: Clinical Trials to Assess Dose. Early trials
investigating the use of immunologically active compounds
in a variety of human malignancies bore mixed results but
provided the scientiﬁc rationale for further investigating
the role of immunological mediators in the treatment of
human malignancies. Several reports in the early 1980s sug-
gested that IFN-α therapy resulted in objective responses in
melanoma—galvanizing theoncologicaland pharmaceutical
community to assure commercial production of the agent,
using rDNA technology. Currently, three subspecies of IFN-
α are available commercially: IFN-α2a (Roferon-A, Roche
Pharmaceuticals, Nutley, NJ), IFN-α2b (Intron A, Schering
Plough, Kenilworth, NJ), and IFN-α2c (Berofor, Boehringer
Ingelheim, Vienna, Austria).
A multitude of phase II trials followed—testing various
doses schedules and routes of recombinant and nonrecombi-
nant IFN-α in metastatic melanoma to attempt to identify an
optimal dose, schedule, and treatment duration with accept-
able toxicity to induce response in metastatic melanoma
(see Table 1). Response rates with IFN (approximately 16%)
were similar to those seen with single-agent chemotherapy,
but already durable responses were seen in some subjects,
lasting years. It was noted that response rates were higher
in patients with smaller disease burden, suggesting that the
most eﬀective results might be obtained in patients with
microscopic disease treated in the adjuvant setting.
A ﬂurry of trials examined the role of adjuvant IFN
therapyforhigh-riskmelanoma.Thesetrialsaresummarized
below (see Table 2) divided based on IFN-α2 dose: low-dose
(<3MU/dose), intermediate dose (5–10MU/dose), and high
dose (>10MU/dose).
3.3.3. IFN Therapy: Clinical Trials of High-Dose IFN. Two
high-dose regimens suggested promise in North American
trials completed in 1990. The North Central Cancer Treat-
ment Group (NCCTG) trial tested a high 20MU/m2 dose
of IFN-α2a administered intramuscularly thrice weekly for
twelve weeks for stage II and III disease [20]. Median disease
free survival (DFS) and overall survival (OS) were improved
with treatment but did not achieve statistical signiﬁcance;
the lower stage II patients did not appear to beneﬁt as
much as the higher risk patients with this adjuvant therapy.
The second trial—the E1684 Eastern Cooperative Group
(ECOG) trial—tested an induction phase of one month of
daily intravenous (IV) IFN-α2b, followed by a prolonged (11
months) maintenance therapy with doses that approached
the maximum tolerable dosage given subcutaneously (SC)
[21].
E1684 was the ﬁrst randomized controlled trial to show
a signiﬁcant prolongation in both DFS and OS among
patients with deep primary tumors (>4mm, T4N0M0), or
thepresenceofregionallymphnodemetastases(TxN1-3M0,
AJCC stage III). Notably, the trial required that all patients
undergo pathologic staging of regional lymph nodes before4 Journal of Skin Cancer
Table 1: Phase II trials of IFN-α for metastatic melanoma.
Study
reference
No. of
enrolled
patients
(followup)
Therapy and
IFN
subspecies
Dose—treatment
arm (MU/m2)
Schedule—
treatment
arm
ORR CR PR
Ernstoﬀ
et al.
1983 [82]
17 α2b 10–100 5d/week× 1
month N/A N/A 2
Creagan
et al.
1984 [83]
23 α2a 50 Thrice weekly × 12
weeks 20 1 5
Creagan
et al.
1985 [84]
350 α2a +
cimetidine 50 Thrice weekly × 12
weeks 23 0 8
Creagan
et al.
1984 [85]
31 α2a 12 Thrice weekly × 12
weeks 23 3 4
Legha
et al.
1987 [86]
62 α2a
1st
arm—escalating
(3–36 × 106 U/d)
2nd arm—ﬁxed
dose (18 ×
106 U/d)
1st arm—daily
during induction
followed by thrice
weekly
2nd arm—thrice
weekly
1st—12.9%
2nd—16.1%
1st 0
2nd 0
1st—9.7%
2nd—6.5%
Hersey
et al.
1985 [87]
200 α2a 15–50 Thrice weekly 10 2 0
Neefe
et al.
1990 [88]
97 α2a Escalating: 3 to 36
× 106 U
Daily for 10 days
then 70 days total 86 2
Dorval
et al.
1986 [89]
22 α2b 10 Thrice weekly 24 2 4
Coates
et al.
1986 [90]
15 α2a 20 5d/weekevery2
weeks 00 0
enrolment and excluded in transit, satellite, or extracapsular
spread of disease. Patients received an induction phase
consisting of IFN-α2b IV at 20MU/m2 daily for 5 days
per week for 4 weeks followed by a maintenance phase
of thrice weekly SC injections at 10MU/m2 for 48 weeks
(HDI) versus close clinical follow-up. After a median follow-
up period of more than 6.9 years, there were signiﬁcant
diﬀerences in relapse and survival; the estimated 5-year
relapse free survival (RFS) in the treatment arm was 37%
(95% conﬁdence interval [CI], 30–46%) versus 26% (95%
CI, 19–34%) in the control group, while the 5-year OS in was
46%(95%CI,39–55%)versus37%(95%CI,30–46%)inthe
treatment and observation arms, respectively.
Subgroupanalysisfoundthatpatientswithdeepprimary,
node-negative melanoma (T4N0Mx) were underrepresented
(11% of the total number, 280). Analysis also revealed that
the node-positive patients (stage III disease) beneﬁted the
most from IFN-α2b therapy, with the greatest reduction of
relapse early during the ﬁrst several months of treatment.
In fact, the greatest improvement in survival (hazard ratio)
was seen in patients with clinically node-negative but
pathologically positive nodes (N1 disease). The results of this
groundbreaking trial led the United States Food and Drug
Administration (FDA) to approve IFN-α2b for commercial
use,andIFN-α2bundertheECOG1684protocolbecamethe
standard of care for high-risk operable melanoma patients.
HDI with a 4-week induction phase followed by a 48-
week subcutaneous maintenance phase remains the only
adjuvant therapy to date that has demonstrated survival
beneﬁt in addition to durable relapse-free survival rates in two
independent randomized cooperative group studies. Signiﬁcant
treatment-related adverse events (AEs) raised the question as
towhetherlow-doseIFN-αgivenforalongerdurationwould
be similarly eﬀective with an improved toxicity proﬁle.
ECOG and the US intergroup therefore compared
therapy with HDI for 1 year versus low-dose IFN-α2b (LDI)
(thrice weekly SC injections at 10 MU/m2) for 2 years versus
observation in E1690 [22]. RFS was signiﬁcantly improved
in the HDI population versus observation (HR = 1.28,
P = 0.025). Although LDI was associated with a reduced
fraction of grade 3/4 AEs compared to HDI (1 [0.5%]
versus 17 [8.0%] grade 4 AEs, resp.), LDI failed to achieve
statistically signiﬁcant durable improvement in RFS. Neither
LDI nor HDI appeared to have any durable impact on OSJournal of Skin Cancer 5
Table 2: Phase III studies of IFN-α for metastatic melanoma.
Study
reference
No of
patients
eligible for
analysis
TNM stage Therapy and
IFN subspecies
Dose and
schedule—treatment
arm
Median
followup at
time of
reporting
(yrs)
Median
DFS
(mths)
Median OS
(mths)
%N o d e -
positive
High dose
NCCTG
83-7052 [20] 262
II–III (T2-
4N0M0/TanyN +
M0)
IFN-α2a versus
observation
IM 20MU/m2 thrice
weekly for 4 months 6.1 NS NS 61
ECOG E1684
[21] 287
II–III
(T4N0M0/TanyN
+M 0 )
IFN-α2b versus
observation
IV 20MU/m2 5d a y sa
week for 4 weeks →
then →SC 10MU/m2
3d a y saw e e kf o r4 8
weeks
12.6 6.9
S( a t
6.9yrs) NS
(at 12yrs)
89
ECOG E1690
[22] 642
II–III
(T4N0M0/TanyN
+M 0 )
IFN-α2b—high
dose versus low
dose versus
observation
High dose:
IV 20MU/m2 5d a y sa
week for 4 weeks →
then → SC 10MU/m2
3d a y saw e e kf o r4 8
weeks
Low dose:
SC 3MU/m2 2d a y sa
week for 2 years
6.6 4.3 NS 74
ECOG E1694
[23] 774
II–III
(T4N0M0/TanyN
+M 0 )
IFN-α2b versus
GMK vaccine
IV 20MU/m2 5d a y sa
week for 4 weeks →
then → SC 10MU/m2
2d a y saw e e kf o r4 8
weeks
2.1
62% (2yr)
versus
49%
78% versus
73% 77
ECOG E2696
[25] 107
II–III–IV (stage IV:
resectable meta
static disease)
IFN-α2b with
GMK vaccine
with and
without
induction
Induction:
IV 20MU/m2 5d a y sa
week for 4 weeks →
then →SC 10MU/m2
3d a y saw e e kf o r4 8
weeks
No induction:
SC 10MU/m2 3d a y sa
week for 48 weeks
2.4 S S Not
available
Intermediate dose
EORTC 18952
[31] 1388
II–III
(T4N0M0/TanyN
+M 0 )
IFN-α2b for 1yr
versus 2yrs
versus
observation
IV 10MU 5 days a
week for 4 weeks →
then →SC 10MU 3
days a week for 1 year
OR SC 5MU 3 days a
week for 2 years
1.6 7.2% (NS) 5.4% (NS) 74
EORTC 18991
[91] 1256 III (TanyN + M0)
PEG IFN-α2b
versus
observation
SC 6μg/kg/week for 8
weeks → then →SC
3μg/kg/week for 5
years
3.8
45.6%
versus
38.9%
(NS)
NS 100
Low dose
Austrian
melanoma
cooperative
group
(AMCG) [92]
311 II (T2-4N0M0) IFN-α2a versus
observation
SC 3MU 7 days a week
for 3 weeks → then
→SC 3MU 3 days a
week for 1 year
3.4 S Not
available 0
French
melanoma
cooperative
group
(FCGM) [93]
499 II (T2-4N0M0) IFN-α2a versus
observation
SC 3MU 3 days a week
for 18 months >3 0.74 (HR),
S
0.70 (HR),
S 06 Journal of Skin Cancer
Table 2: Continued.
Study
reference
No of
patients
eligible for
analysis
TNM stage Therapy and
IFN subspecies
Dose and
schedule—treatment
arm
Median
followup at
time of
reporting
(yrs)
Median
DFS
(mths)
Median OS
(mths)
%N o d e -
positive
WHO
melanoma
program trial
16 [94]
444 III (TanyN + M0) IFN-α2a versus
observation
SC 3MU 3 days a week
for 36 months 7.3 NS NS 100
Scottish
melanoma
cooperative
group [45]
96
II–III (T3-
4N0M0/TanyN +
M0)
IFN-α2a versus
observation
SC 3MU 3 days a week
for 6 months >6N SN S Not
available
EORTC
18871/DKG
80-1 [42]
728
II–III (T3-
4N0M0/TanyN +
M0)
IFN-α2b versus
IFN-γ versus
ISCADOR M
versus
observation
IFN-α2b:
SC 1MU every other
day for 12 months
IFN-γ:
SC 0.2mg every other
day for 12 months
8.2 NS NS 58
UKCCCR/AIM
HIGH [44] 674
II–III (T3-
4N0M0/TanyN +
M0)
IFN-α2a versus
observation
SC 3MU 3 days a week
for 24 months 3.1 NS NS Not
available
DeCOG [95] 840 III (T3anyN + M0) IFN-α2a
SC 3MU 3 days a week
f o r1 8m o n t h s( A )
versus 5yrs (B)
4.3
81.9%
versus
79.7% NS
85.9%
versus
84.9% NS
Not
available
DeCOG [34] 444 III (TanyN + M0) IFN-α2a
SC 3MU 3 days a week
f o r2 4m o n t h s( A )
v e r s u sS C3M U3d a y s
a week for 24months +
DTIC 850mg/m2 every
4–8 weeks for
24months (B) vesus
observation (C)
3.9
HR: 0.69
(A) versus
1.01 (B)
versus 1.0
(C)
HR: 0.62
(A) versus
0.96 (HR)
(B) versus
1.0 (C)
100%
Keys: NS—not signiﬁcant; S—signiﬁcant; HR—hazard ratio.
in this trial. Retrospective analysis revealed that 37 patients
had crossed over from the observation arm to the HDI arm
oﬀ-protocol at the time of regional recurrence—which may
have attenuated any apparent survival beneﬁt.
E1694 was an intergroup US study that accrued 880
patients and was designed to evaluate the beneﬁt of vaccina-
tion with the ganglioside GM2/keyhole limpet hemocyanin
vaccine (GMK) in relation to HDI [23]. The GMK vaccine
consisted of puriﬁed ganglioside GM2 coupled to keyhole
limpet hemocyanin (KLH). Vaccination induced antibodies
against GM2 that were capable of speciﬁcally binding GM2
and killing melanoma cells in vitro through complement
or antibody-dependent cell-mediated cytotoxicity (ADCC).
GMK vaccination induced more consistent high-titer IgM
and IgG antibodies than the original GM2-BCG vaccine
that had previously improved RFS in stage III melanoma
at MSKCC [24]. In this trial, HDI proved to be superior
with improved RFS (HR = 1.47,P = 0.0015) and OS
(HR = 1.52,P = 0.009) compared to GMK. Following
an interim analysis in April 2000 that showed a mortality
beneﬁtfor HDI,it wasfeltto be ethicallydiﬃcult to continue
the GMK intervention, and this trial was closed. Subsequent
analysis found that GMK had induced antibody responses
in 80% of vaccinated patients, and that those patients who
had developed anti-GM2 antibody response showed a trend
to improve outcome compared to those without immune
response—indicatingthatalackofimmuneresponsewasnot
to blame. Post hoc intention-to-treat analysis conﬁrmed the
improved RFS (HR = 1.49) and OS (HR = 1.38) for HDI.
E2696 was an ECOG-sponsored randomized, phase II
trial that enrolled 107 patients with resected stage IIB, stage
III, and stage IV disease (including patients with resectable
intransit metastases or extracapsular extension of nodal
disease [formerly AJCC designated stage IV, M1 disease
but currently classiﬁed as AJCC stage IIIC disease]) [25].
The trial comprised 3 treatment arms—arm A (GMK plus
concurrent HDI), arm B (GMK plus sequential HDI), and
arm C (GMK alone). When results were analyzed at a
median follow-up period of 24 months, the combination
of HDI/GMK appeared to reduce the risk of relapse when
comparedtoGMKalone(HR=1.75forCversusAandHR=
1.96 for C versus B).
In a pooled analysis of all four ECOG-led trials of HDI
published in 2004 [26], the survival of patients enrolled inJournal of Skin Cancer 7
the afore-mentioned E1684, E1690, E1694, and E2696 trials
wasupdated.Survivalandrelapse-freeoutcomeanalysiswere
calculated based on data from 713 patients randomized to
HDI versus observation in E1684 and E1690. This subse-
quent analysis again showed the beneﬁt of HDI in terms of
improved RFS (HR = 1.30, P<. 006). The signiﬁcant mortal-
ity beneﬁt noted in the ﬁrst mature report of E1684 was not
signiﬁcant in the pooled analysis (HR = 1.08 for non-IFN-
treated versus IFN-treated arms, P = 0.42). As mentioned
earlier, this observation was qualiﬁed by the confounding of
E1690bythecrossoverofobservation-assigned patients(n =
37) who developed regional recurrence after assignment to
observation and subsequently received HDI and omission of
this data from E1694 because the comparator arm was the
vaccine GMK rather than observation.
3.3.4. IFN Therapy: Follow-Up Trials Utilizing HDI. Survival
analysis in E1684 had noted that the greatest apparent
reduction of relapse occurred relatively early, suggesting that
the induction phase had a critical role to play. The Hellenic
trial [27] attempted to validate this hypothesis prospectively
withaphaseIIIstudythatrandomizedpatientstoamodiﬁed
induction phase of 15MU/m2 HDI only versus the same
induction with a modiﬁed maintenance phase in which
10MU(notperm2)wasadministeredTIWformaintenance.
The noninferiority study design proposed that the one-
month treatment would be considered at least as good as
the one-year regimen treatment if the relapse rate at 3 years
from study entry was no more than 15% higher in the
one-month treatment arm. A sample size of 152 patients
per treatment arm was planned, and the study enrolled
364 patients in total (182 patients per arm). At a median
followup of 5.25 years, there was no statistically signiﬁcant
diﬀerence in either median RFS or OS. The trial concluded
that at the 5% level of signiﬁcance the 3-year relapse rate of
the one-month group was not 15% higher than the relapse
rate of the one-year group. This trial’s results have to be
interpreted in light of two factors. First, the noninferiority
trial design implies that the trial was not powered to detect
small diﬀerences in RFS between the two arms. Second, the
study utilized nonstandard IFN-α2b doses of 15MU/m2 for
induction and a ﬂat maintenance dose of 10MU/day rather
than the 20MU/m2 induction and 10MU/m2 maintenance
doses of the E1684 regimen approved by the FDA.
A more recent US intergroup study (E1697) also
attempted to test this hypothesis in patients with resectable
intermediate risk melanoma (≥T3 or any thickness with
microscopically positive node disease—N1a-N2a). 1150 of a
planned 1420 patients were randomized to either 4 weeks of
HDI (20MU/m2/day for 5 days weekly) versus observation
[28]. This study was closed for futility in 2010 and presented
to ASCO in 2011, revealing a lack of any impact upon
either RFS or OS with IFN. The study demonstrated a
5-year survival rate for IFN 0.82 (95% CI 0.78–0.86)
versus observation 0.85 (95% CI 0.81–0.89) with conditional
probability analysis of the study showing a less than 1%
chanceofshowingthedesired7.5%reductioninrelapserate,
even if taken to completion. Notably ulceration was present
in 36% of patients, and 19% had microscopic node positive
disease, so that the risk proﬁle was somewhat less than
originally anticipated—leading to concern that the study was
underpowered to detect OS/RFS beneﬁt in the segment of
patients best suited for it.
Another observation from the pivotal E1684 study was
that the greatest improvement in survival (hazard ratio) was
seen in patients with clinically negative but pathologically
positive nodes (N1 disease). The Sunbelt Melanoma Trial
[29] was an ambitious trial designed to evaluate whether
patients with a single positive sentinel lymph node biopsy
who went on to complete lymph node resection beneﬁted
from subsequent HDI. Eligible patients had primary
melanomas with Breslow thickness of ≥1.0mm were
subsequently staged with sentinel lymph node (SLN) biopsy.
In the intention-to-treat portion (Protocol A) of the study,
SLN-positive patients were randomized to either HDI
(induction and maintenance per the FDA-approved E1684
protocol) or observation following complete lymph node
dissection. This trial never achieved its stated accrual goals
and was severely underpowered as analyzed in the interim.
The intention-to-treat analysis of Protocol A revealed no
signiﬁcant diﬀerences in either DFS (HR = 0.82, 95% CI
0.47–1.40) or OS (HR 1.07, 95% CI 0.65–1.78) between
patients randomized to HDI versus observation. (The
small numbers here qualify any interpretation of this trial,
but the HR of .82 is identical to the beneﬁt reported for
intermediate dosages of PegIFN at the FDA review of that
agent, which resulted in its approval based upon early
results of that trial this year). This complicated trial also
included a secondary protocol (Protocol B) that attempted
to assess the utility of molecular staging for SLN specimens.
Patients with negative SLN by standard histopathology and
immunohistochemistry underwent molecular staging by
reverse transcriptase polymerase chain reaction (RT-PCR)
to detect melanoma-speciﬁc mRNA (tyrosinase, MART
1, MAGE 3, gp100). Patients with SLN-positive disease
by RT-PCR were then randomized to observation versus
completion lymph node dissection (CLND) versus CLND
+I N F α2b (E1684 induction phase only). Analysis of the
Protocol B results found no signiﬁcant diﬀerences in DFS or
OS among patients randomized to CLND or CLND + IFN-
α2b versus observation, but the inadequate numbers accrued
to this trial again qualify any conclusions from the study.
TheItalianMelanomaIntergrouprecentlypresenteddata
from a randomized phase III study that assessed the utility
of a shorter but more intense course of HDI (intensiﬁed
HDI, IHDI) at ASCO 2011 [30]. 336 patients with stage III
disease were randomly assigned to standard HDI therapy
or 4 cycles of IFN-α2b 20MU/m2 intravenously 5 days a
week for 4 weeks every other month (IHDI). At 5 years,
the RFS and OS rates in the IHDI arm were 45.8% (95%
CI 37.4–53.7) and 60.1% (95%CI 53.0–66.5), whilst the
corresponding rates in the standard HDI arm were 44.3%
(95% CI 35.7–52.6) and 52.7% (95%CI 44.9–59.8) with no
statistically signiﬁcant diﬀerence between the two groups.
More importantly, the discontinuation rate and overall
toxicity proﬁles were relatively similar in both groups—
suggesting that the shorter but more intensive IHDI regimen8 Journal of Skin Cancer
may be more feasible than conventional HDI. However,
mature survival data has yet to accrue for this combination,
and it lacks the validation of conventional HDI.
Considering all available evidence for adjuvant HDI, it
is clear that there is a uniform unquestionable improvement
in RFS with IFN-α, with a smaller but reproducible beneﬁt
upon OS evident in two trials of HDI, and meta-analyses
of all reported trials of IFN irrespective of dosage. E1684
demonstrated a statistically signiﬁcant survival beneﬁt that
was not reproduced in E1690, where the issue of crossover
was recognized and documented; the beneﬁt upon survival
wasequal to the beneﬁt upon survival in E1694, documented
inrelationtothevaccineGMKthatwasatissueuntilrecently.
The pooled analysis of E1684/E1690/E1694/E2696 and
several meta-analyses have found strong evidence for pre-
vention of relapse by IFN, with signiﬁcant but smaller
improvements in overall survival that appears to be greatest
in patients with ulcerated primaries and/or patients with
node-positive disease—a proposition will be tested in the
upcoming EORTC 18081 trial. Taken together, the above
results have supported the initial US FDA approval and
resulted in sustained approval of high-dose IFN-α by the US
FDA.
3.3.5. IFN Therapy: Low and Intermediate Dosing and Dura-
tion of Therapy. In an eﬀort to improve upon the toxicity
of HDI, less intensive regiments were tested by several
authors. These included intermediate (5–10MU/m2), low
(≤3MIU/m 2), and very low (1MIU/m2) dosing regimens,
and the trials are summarized in Table 2 (Table 2—phase III
studies of IFN-α for metastatic melanoma).
Although some of these trials demonstrated a beneﬁt in
RFS for the IFN arm relative to placebo, these diﬀerences
tended not to be durable. The EORTC (European Organiza-
tion for Research and Treatment of Cancer) 18952 trial [31]
assigned1388patientswithstageIIB/IIIdiseasetooneoftwo
intermediate dosing schedules (four weeks of induction with
10MU ﬁve times per week, followed by either 10MU thrice
weekly for one year or 5MU thrice weekly for two years)
versus observation. At the relatively early time point of 4.5
years, patients treated for two years were more likely to be
free of distant metastasis than those treated for one year or
managed with observation only (47% versus 43% and 40%,
resp.). OS was greater in the two-year treatment arm (53%)
compared to the one-year arm and observation (48% each).
These diﬀerences did not reach statistical signiﬁcance.
Apart from dosage variations, several investigators have
experimented with the duration of IFN-α therapy, based on
observations from small early trials and the large French
multicenter trial that suggested that the eﬀect of interferon
on RFS disappeared rapidly on cessation of treatment [32].
A meta-analysis of 12 randomized trials by Wheatley et al.
[33] had shown that IFN-α therapy reduced odds of recur-
rence and the risk of death compared with observation or
vaccination without deﬁning the optimum dose or duration
of interferon therapy.
A randomized Phase III Dermatologic Cooperative
Oncology Group (DeCOG) study [34] evaluated the utility
of the LDI/Dacarbazine (DTIC) in 444 patients with micro-
scopic or macroscopic regional node metastases following
surgery and complete lymphadenectomy who were at a high
risk of recurrence. Comparator arms were SC 3MU 3 days a
week for 24 months (A) versus SC 3MU 3 days a week for 24
months + DTIC 850mg/m2 every 4–8 weeks for 24 months
(B) versus observation (C). At approximately 4 years of
followup, the low-dose IFN combination was associated with
an improvement in DFS (HR = 0.69) and OS (HR = 0.62)—
the second study to demonstrate a survival beneﬁt for IFN-
α therapy after E1684. It must be noted, however, that this
trial was only powered to assess if DTIC adds any beneﬁt to
IFN-α and not whether low-dose IFN-α therapy was indeed
superior to observation. These results are also inconsistent
with earlier Austrian, French, and UK studies that have
already been cited, which demonstrate no OS beneﬁt of LDI.
A subsequent randomized study by the same group
then evaluated LDI therapy in patients with intermediate-
high-risk disease (T ≥ 1.5mm) and negative clinical lymph
node status [35]. It compared INF-α at 3MU thrice weekly
subcutaneously for either 18 months (arm A) or 60 months
(arm B). Approximately 75% of all patients had SLN
evaluation with a similar rate of positivity in both groups.
Relevant prognostic factors including Breslow depth were
well balanced between both groups. RFS, DFS, and OS
were similar in all 3 groups with no apparent beneﬁt with
increasing duration of therapy.
TherecentlypublishedNordicIFNtrialwasaprospective
multicenter randomized phase III trial designed to see if
an extended duration of intermediate-dose IFN-α2b (IDI)
therapy would improve RFS compared to observation [36].
Studyinvestigatorscomparedtwodiﬀerentschedules(induc-
tion 10MU SC 5 days weekly for 4 weeks followed by
maintenance 10MU SC thrice weekly for either 12 or 24
months) of IFN-α2b to observation for patients with high
risk cutaneous melanoma (T4N0M0/TxN1-2M0) with no
evidence of distant metastasis or had undergone surgery for
regional lymph node metastases. At a median follow-up time
of 6 years, the authors found that 1 year of maintenance
therapy signiﬁcantly improved median RFS compared to
controls—37.8 months [1-year arm] versus 23.2 months
[controls] and 28.6 months [2-year arm] (P = 0.0.34).
Surprisingly, 2-year therapy did not achieve a signiﬁcant
increase in RFS, where the 2-year therapy in EORTC 18952
had been most eﬀective—although this may be a peculiarity
of this trial [30]. Unlike HDI in E1684, the Nordic IFN trial
did not record a signiﬁcant improvement in OS compared
with untreated controls.
3.3.6. IFN Therapy: PEG-IFN Therapy and Duration. Pegy-
lated IFN (PEG-IFN) is a form of recombinant human
IFN that has been chemically modiﬁed by the covalent
attachment of a polyethylene glycol moiety that results in
sustained absorption and prolonged half-life and has been
showntoincreaseeﬃcacycomparedwithnonpegylatedIFNs
in hepatitis C patients [37–39].
EORTC 18991 investigated the eﬃcacy and safety of
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resected AJCC stage III melanoma. Peg-IFN-α2b therapy
comprised induction dose (Peg-IFN-α2b SC 6μg/kg a week
for 8 weeks) followed by maintenance dose (once weekly SC
injections at 3μg/kg for 5 years) [40]. Pegylated IFN-α2b
(PegIntron, Schering-Plough) was approved by the FDA in
October 2009 on the basis of these results. The investigators
recently presented 7.6-year follow-up data—which showed
an improved RFS in the treatment arm (HR 0.87, 95%
CI 0.76–1.00, P = 0.05) with no diﬀerence in OS/DMFS
between treatment and observation arms. Subgroup analysis
suggested that patients with microscopic nodal metasta-
sis and ulcerated primaries beneﬁted more from therapy
in terms of RFS, OS, and DMFS—an unplanned subset
analysis beneﬁt that has been maintained at longer-term
followup,wheretheoverallbeneﬁtuponrelapse-freesurvival
has eroded from 18% to 13% beneﬁt (P = 0.01 →
0.05). This observation is slated for testing in EORTC trial
18081.
Low-dose pegylated IFN-α2b was evaluated against LDI
in the European Association of Dermato-Oncology (EADO
trial) that prospectively enrolled 896 patients with resected
stage IIA-IIIB melanoma (T ≥ 1.5mm, without clinically
detectable nodal disease) in a phase III trial. Patients were
randomized to receive either 36 months of low-dose peg-
IFN-α2b (100mcg SC once weekly) or 18 months of LDI
(3MUSCthriceweekly).RFS,OS,anddistantmetastasisfree
survival (DMFS) were similar in both groups. Analyses were
likely aﬀected by the high dropout rate (72% before study
end) secondary to serious adverse events in the peg-IFN arm
(44.6% versus 26.6%) [41].
3.3.7. IFN Therapy: Meta-Analyses. Several meta-analyses
have attempted to consolidate and review the available out-
come data on IFN therapy [9–12].
A 2010 meta-analysis of data from randomized clinical
trials (RCTs) published between 1990 and 2008 reviewed a
total of 8122 patients, of whom 4362 patients received IFN-α
[12]. In 12 of the 14 trials, single-agent IFN-α was compared
with observation, and 17 comparisons (IFN-α versus com-
parator) were generated in total. The meta-analysis showed
a statistically signiﬁcant reduction in recurrence for patients
receiving IFN-α (HR = 0.82, 95% CI 0.77–0.87, P<0.001).
Mostinterestingly,whenanalyzedbysubgroup,noparticular
IFN-α regimen, IFN-α type, TNM disease stage, or study
design conferred any statistically signiﬁcant diﬀerences in
overall hazard ratio estimates.
When original data from 12 of the 14 RCTs that assessed
the impact of IFN-α on OS were used to reassess OS, 4 of the
14 comparators (n = 2110) found a statistically signiﬁcant
OS advantage in favor of patients treated with IFN-α.M e t a -
analysis revealed a statistically signiﬁcant reduction in the
risk of death for patients allocated to the IFN-α arm (HR for
death = 0.89, 95% CI 0.83–0.96, P = 0.002). No diﬀerence
in results was found when original data was substituted
for updated data—including the updated OS analysis from
E2696 (the original had analyzed DFS).
TheauthorsconcludedthatIFN-αtherapydemonstrated
improvement in both RRFS (risk reduction = 18%) and OS
(risk reduction = 11%) of patients with high-risk cutaneous
melanoma in a statistically signiﬁcant fashion.
3.3.8. IFN Therapy: Reﬁning the Dose and Duration of IFN
in Adjuvant Therapy for Melanoma. While HDI has consis-
tently demonstrated improved RFS, none of the alternative
low, very low, or intermediate dosing regimens has demon-
strated durable sustained improvements in either RFS or OS.
These include the very low dose (1MU SC every other day)
tested in EORTC 18871 (stage IIB/III) [42], low dose (3MU
SCthriceweekly)testedinWHOmelanomaprogramtrial16
(stage III) [43], E1690 (T4, N1) [22], UKCCCR AIM-High
trial (stage IIB/III) [44], and the Scottish trial (stage IIB/III)
[45].WhilstanOSandDFSbeneﬁtwasnotedintheLDIarm
ofthe2008DeCOGtrial[34]thatevaluatedthecombination
of low-dose IFN and DTIC in patients with microscopic or
macroscopic regional node metastases following surgery and
complete lymphadenectomy, it must be noted that this trial
was not powered to assess the eﬃcacy of LDI.
When considering the trials that tested the intermediate
dose of IFN-α, although EORTC 18952 (stage IIB/III) [31]
demonstrated a 7.2% increase in DMFS, this was not statisti-
cally signiﬁcant and no sustained OS beneﬁt was observed.
The Hellenic trial 13A/97 assessed the role of induction
phase therapy with modiﬁed HDI—several issues including
the noninferiority design as well as the use of nonstandard
IFN-α2b doses in the induction and maintenance phases led
several investigators to revisit the issue of an abbreviated
HD IFN course [46]. Investigators in Beth Israel Deaconess
Medical Center retrospectively identiﬁed 86 patients with
IIB-IIIA melanoma treated between 2002 and 2009 [47].
Whilst all patients had received standard induction therapy
for 4 weeks (IFN-α2b IV at 20MU/m2 daily for 5 days per
week), maintenance therapy (thrice weekly SC injections at
10MU/m2) duration was either 48 weeks (patients treated
prior to January 2006) or 12 weeks (patients treated between
January 2006 and January 2008). RFS at 3 years was 80%
in the 12-week cohort and 87% in the 48-week cohort
(P = 0.41), whilst OS at 5 years was 90% in the 12-
week cohort and 88% in the 48-week cohort (P = 0.99).
Study investigators noted that whilst RFS/OS were similar
in patients with IIB/IIIA disease, RFS appeared worse in
patients with IIC disease. However, despite the statistical
nonsigniﬁcance of these results, the use of a modiﬁed
HDI dose-schedule that may increase compliance merits
investigation in a prospective randomized trial involving
intermediate risk patients and with a control group so that
the activity of this regimen can be gauged.
3.4. Identifying Prognostic Factors of IFN Therapy for Mela-
noma. Muchofwhatwehavelearnedinthepasttwodecades
suggests that in patients with high-risk disease, adjuvant
IFN-α2btherapyhasaremarkablyconsistentbeneﬁcialeﬀect
on RFS but a lesser impact upon survival, especially after 10
years.
The attenuation in survival beneﬁt over time may be
explained by several factors. Firstly, with increasing survival
other competing sources of mortality may cause death.10 Journal of Skin Cancer
Secondly, there is increasing evidence that IFN-α plays a role
in vascular damage through promotion of antiangiogenesis.
High levels of IFN-α result in transcriptional repression
of IL-1α and IL-1β, IL-1R1 and VEGF-A thereby altering
the balance between endothelial cell apoptosis and vascular
repair. [46] Evidence from the rheumatologic literature
suggests that this may explain the increased rate of car-
diovascular events in patients with active systemic lupus
erythematosus [48, 49]. Evidence from multiple intergroup
trials buttressed by European data suggests that a certain
subgroupofpatients(ulceratednode-positivedisease)obtain
greater beneﬁt with IFN-α2b therapy whilst others beneﬁt
less, if at all. This suggests that focusing IFN-α2b therapy
for this group of patients with ulcerated tumors which
comprised a subset that was not speciﬁed for analysis in
prior trials may result in improved outcomes including
sustained OS beneﬁts although the fact that prior analysis of
multiple ECOG and US Intergroup trials have not identiﬁed
u l c e r a t i o na sap r e d i c t o ro fi m p r o v e db e n e ﬁ ti so fc o n c e r n .
The results of EORTC 18081 are awaited to evaluate this
question.
Autoimmune manifestations are a known feature of
IFN therapy in chronic viral hepatitis and hematologic
malignancies. These include the appearance or increase in
titers of autoantibodies or less commonly, the occurrence
of overt autoimmune diseases, especially of the thyroid. The
prognostic importance of the development of autoimmunity
in these diseases is unclear. However, in the melanoma
context, the concurrent appearance of autoimmune phe-
nomenon has long been considered a good prognostic factor
[50].
In both E2696 and E1694, the development of autoim-
munity following IFN-α therapy was associated with an
improved outcome [51, 52]. However, the ﬁrst prospectively
validated analysis of autoimmunity as a biomarker for IFN
response was published by Gogas et al. in 2006 [53]. The
Hellenic trial was a noninferiority study designed to assess
the importance of the induction phase of HDI therapy.
In a substudy of this 364 patient trial, 200 patients had
blood samples drawn at baseline, and subsequently at 1,
3, 6, 9, and 12 months of therapy and assayed for various
autoantibodies. Interestingly, it was noted that the overall
incidence of autoantibodies or autoimmune manifestations
amongst patients receiving therapy for one year was greater
than amongst those who only had induction therapy—but
only barely (28% versus 24%). Strikingly, the patients who
developed autoimmune manifestations had better DFS and
OS—at a median followup of 46 months, patients with
evidence of autoimmunity had improved reductions in the
rate of relapse (13% versus 73%) and of overall mortality
(4% versus 54 %) compared to those who did not develop
autoantibodies.
Speciﬁc human leukocyte antigen (HLA) classes I and
II antigens have been associated with greater response to
therapy and OS in patients with metastatic melanoma
treated with interleukin-2 [54, 55]. Gogas et al. analyzed
the Hellenic trial with respect to HLA allele frequencies
between patients with and without recurrences after HDI
therapy. At a median followup of 70.67 months, the authors
noted that HLA-Cw∗06-positive patients had a better RFS
and OS (P = 0.013 and P = 0.025, resp.). Even correcting
for the presence of autoimmunity, this diﬀerence remained
statisticallysigniﬁcantforimprovedRFSintheHLA-Cw∗06-
positive cohort (P = 0.020) [56].
Investigators at the University of Pittsburgh and ECOG
have evaluated the E2696 and E1694 trials to better under-
standtheprognosticvalueofautoimmunityinducedbyHDI.
Sera from 103 patients in E2696 and 691 patients in E1694
banked at baseline and up to 3 additional time points were
tested by ELISA for the development of 5 autoantibodies.
In E2696, autoantibodies were induced in 17 subjects (25%;
n = 69) receiving HDI and GMK versus 2 (6%; n =
34) receiving GMK without HDI (2P value =.029). Of 691
patients in E1694, 67 subjects (19.3%; n = 347) who
received interferon developed autoantibodies versus only 15
(4.4%; n = 344) in the vaccine control group (2P value <
0.001). In the HDI arms, almost all induced autoantibodies
were detected at ≥12 weeks after initiation of therapy.
A landmark analysis of E1694-resected stage III patients
showed survival advantage associated with HDI-induced
autoimmunity that approached statistical signiﬁcance after
adjusting for treatment (HR = 1.54; P = 0.072) [52]. Whilst
the development of autoimmunity is a useful surrogate to
assess response in IFN therapy, an inability to test for it prior
to treatment limits its potential in this regard.
Methylthioadenosine phosphorylase (MTAP) catalyses
the phosphorylation of methylthioadenosine (MTA), a by-
productofpolyaminesynthesis.Immunohistochemicalanal-
ysis comparing benign melanocytic nevi to melanomas
has shown an inverse association between MTAP protein
expression and progression of melanocytic tumors. MTAP
alsoplaysasigniﬁcant rolein theactivityofsignal transducer
and activator of transcription 1 (STAT1), an essential com-
ponent for activation of the interferon γ signaling pathway.
Utilizing a tissue microarray analysis of 465 unique patients
with pigmented lesions (ranging from melanocytic nevi
to melanoma metastases), Meyer et al. [57] demonstrated
that MTAP expression was signiﬁcantly associated with OS
(P<0.01) and RFS (P<0.05). STAT 1 expression had
no signiﬁcant prognostic relevance in this analysis. Sub-
group analysis involving 39 patients whose primary lesions
were 1.5–4.0mm and received adjuvant LDI revealed that
patients with MTAP-positive primary melanomas had a
signiﬁcantly longer RFS (P<0.0 5 )a n dO S( m e d i a ns u r v i v a l
80 months versus 35 months) compared to patients with
MTAP-negative tumors. Despite the small numbers and
retrospectivenatureofthestudy,thisobservationbearsmen-
tioning given the accumulated data [58–60] surrounding
pSTAT3 as a biomarker of melanocytic transformation and
the importance of the relative balance of pSTAT1/pSTAT3 in
governing melanocyte diﬀerentiation.
YKL-40, a mammalian chitinase-like protein, is ex-
pressed, and secreted by several types of solid tumors.
Retrospective analyses have shown that elevated YKL-40
levels are an independent prognostic factor of RFS and OS in
stageIandIImelanoma[61,62]andarecorrelatedwithpoor
survivalinpatientswithmetastaticdisease.Apooledanalysis
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IFNinstageIIB-IIImelanoma(NordicStudy,EORTC18952,
and EORTC 18991) evaluated ELSA-determined YKL-40
levels in serum samples that were collected at study outset,
during treatment and at followup every three to six months
for up to 10 years. Univariate analysis of baseline YKL-40
levels in 299 untreated patients demonstrated an association
of higher levels with short OS (HR = 1.28; 95% CI 1.05–1.57,
P = 0.015). When serial values were stratiﬁed by treatment
and analyzed, it was shown that increases in the YKL-40
levels were signiﬁcantly associated with shorter OS in all
treatment arms [63].
Otherserumbiomarkers of interest in melanoma include
S100B, melanoma-inhibiting activity (MIA), and tumor-
associated antigen 90 immune complex (TA90IC). S100B, an
immunohistochemicalmarkerofpigmentedskinlesions,has
prognostic utility in melanoma—with rising concentrations
of serum S100B (above >0.6μg/L) indicating progression of
the disease and a decline indicating response to treatment
[52]. S100B levels have been associated with mortality—
data derived from E1694 has shown that a high baseline
or increasing serum S100B is an independent prognostic
marker of risk for mortality in patients with high-risk dis-
ease. Swiss and German guidelines recommend determining
serum S100B levels in patients with T2 or greater (Breslow
>1mm) lesions every 3–6 months.
MIA is a growth-inhibiting protein that is strongly
expressed in malignant melanomas, but not in benign
melanocytic nevi [64]. A German study [65] of 326 patients
with melanoma (using a cutoﬀ of 9.8ng/mL) reported that
MIAlevelswereelevatedin89.5%and60.0%ofpatientswith
stage IV/III disease, respectively, compared to just 5.6% of
patients with stage I/II disease. A subsequent study of 373
melanoma patients evaluating the combination of S100B,
MIA, LDH, and albumin as biomarkers reported that S100B
had the greatest sensitivity for detecting new metastases
compared to MIA, LDH, or albumin. TA90IC was compared
to MIA and S100B in a prospective 75 patients study
involving stage III melanoma patients undergoing adjuvant
vaccine immunotherapy following completion of lymph
node dissection. Serum samples were drawn beforeinitiation
of immunotherapy and at six follow-up time points. Study
authors noted that TA90IC was the ﬁrst marker to become
elevated in 29 (57%) followed by MIA, and S100B. Mul-
tivariate regression analysis suggested that TA90IC was an
independent predictor of survival when elevation occurred
between 2 weeks and 3 months, whereas MIA was an
independent predictor appearing at 4–6 months. Notably, all
the patients in this study had elevated S100B levels (above
manufacturer’s recommended upper limit of normal) likely
secondary to detection of vaccine-related tumor antigen.
Whilst S100B, MIA and TA90IC may be useful in assessing
prognosis in melanoma, they have not been evaluated as
response markers for IFN-adjuvant therapy for melanoma.
3.5. Non-IFN-Based-Adjuvant Therapy: Chemotherapy.
Non-IFN-based therapies have been investigated in the
adjuvant setting in multiple diﬀerent trials—the most im-
portantrandomizedcontrolledtrials(RCTs)aresummarized
in (Tables 3 and 4—phase II/III studies of chemotherapeutic
agents in melanoma).
Chemotherapy whether as a single agent or in com-
bination with other chemotherapeutics, hormonal therapy,
or biologic therapy has not shown any improvement in
either DFS or OS in any RCT to date except in high-
selected patients under special settings (isolated limb per-
fusion). When biologics were combined with chemotherapy
(biochemotherapy)inthemetastaticsetting,higherresponse
rates and prolongation of median survival were observed
although no OS beneﬁt was noted compared to DTIC
monotherapy.
The South West Oncology Group (SWOG) has led an
intergroup phase III trial of biochemotherapy for 3 months
compared with HDI for one year in stage-resectable IIIB
and IV patients (S0008). The study arm involves three cycles
of cisplatin, vinblastine, DTIC, IL-2, and interferon—with
both the IL-2 and interferon being dosed substantively below
their individual maximally tolerated doses. This study is
therefore better understood as an assessment of the eﬀect
of chemotherapy modulated by IFN/IL-2—at present, it
remains under analysis. However, the negative result of
a recent intergroup study comparing biochemotherapy to
polychemotherapy alone has tempered expectations [66].
The apparent beneﬁt of vindesine in treating stage III
melanoma in the adjuvant setting was suggested in several
single-center studies—but the result has not been repro-
ducible in any RCT. Following suggestion of beneﬁt from
small nonrandomized single-institution studies, further
studies using megestrol acetate, vitamin A, and nonspeciﬁc
immunostimulants such as BCG, Corynebacterium parvum,
and transfer factor have unfortunately turned in negative
results.
Three trials have assessed the use of adjuvant chemother-
apy following surgical resection in high-risk patients—
two demonstrated increases in RFS, whilst no beneﬁt was
observed when DTIC was combined with BCG in the
postoperative setting (E1673) [67]. In the phase III DeCOG
trial comparing adjuvant low-dose IFN to LDI/Dacarbazine
(DTIC) combination to observation in high-risk patients
with regional node metastases following complete lym-
phadenectomy, a survival beneﬁt was only observed in
the low-dose IFN alone arm [34]—however, this trial was
not powered to assess the beneﬁt of low-dose IFN over
observation.
3.6. Non-IFN-Based-Adjuvant Therapy: Vaccine Therapy.
Since1967whenMortonﬁrstinvestigatedtheuseofvaccines
to treat patients after surgery, melanoma vaccines have been
extensively investigated in the hope of eliciting durable
clinical responses with minimal additional toxicity. Vaccines
aim to increase immune recognition and enhance antitumor
responses through improved antigen presentation resulting
in highly durable eﬀector T-cell responses.
Melanoma vaccines can be categorized based on the type
of antigen incorporated—peptide, ganglioside, and whole
cell/cell lysate. Examples of the former include MART-
1/Melan-A, gp100, and tyrosinase—these are melanocyte12 Journal of Skin Cancer
Table 3: Phase II/III studies of chemotherapeutic agents in melanoma.
Study
reference
No. of patients eligible
for analysis (followup)
TNM
stage Treatment arm Median followup at time
of reporting (yrs) OS
Veronesi
et al. 1982
[96]
931 II/III
DTIC
BCG
DTIC + BCG
Obs
5N S
Lejeune
et al. 1988
[97]
325
I,
IIA,
IIB
DTIC
Levamisole placebo 4N S
Fisher et al.
1981 [98] 181 II/III CCNU
Obs 3N S
Koops et al.
1998 [99] 632 II/III
Isolated limb perfusion
+ hyperthermia
Obs
6.4 BS
Keys: NS—not signiﬁcant; S—signiﬁcant; HR—hazard ratio.
lineage antigens recognized by cytotoxic T lymphocytes in
conjunction with HLA-A2.1 and elicit a direct cytotoxic T-
cellresponse.TheseT-cellpeptideantigenshavebeenstudied
inlargemulticenterECOGtrialsthathavegenerallyrecruited
pretreated patients with advanced metastatic melanoma.
Patients who demonstrated immune responses to any of the
peptides develop increased T-cell production of IFN-γ and
had survival times that were nearly double that of patients
who did not develop immunity to 1 or more of the peptide
vaccine epitopes.
MAGE tumor antigens are expressed in a variety of
malignancies including melanoma, non-small-cell lung can-
cer, and head and neck squamous cell carcinoma but
are not detectable in normal tissues except for testis and
placenta [68]. Whilst recognition of the MAGE-3 antigen is
normally limited by HLA haplotype, this can be bypassed
by using protein adjuvants that elicit a broader range of
T-cell responses. A phase II study utilized this approach
to elicit MAGE-3-speciﬁc antibody and T-cell responses
successfully [69]. A randomized phase III trial involving
patients with completely resected stage III melanoma with
detectable MAGE-3-speciﬁc expression in resected lymph
nodes (DERMA study, GlaxoSmithKline) has completed
accrual, and results are expected shortly. This trial is unique
in having incorporated a tumor tissue proﬁle that appears
to predict beneﬁt of vaccine therapy, as preliminarily tested
in patients with advanced melanoma who were vaccinated
against Mage A3 [70]. The results of this trial are expected in
2014.
Gangliosides are sialic acid-containing glycosphingoli-
pids that are overexpressed on surface of melanocytic cells.
It has long been known that de novo responses to the
GM2 ganglioside are associated with extended survival in
melanoma patients. GM2 with bacillus Calmette-Guerin
(bCG) as an adjuvant or combining it with the keyhole
limpet hemocyanin (KLH) hapten and a QS21 adjuvant
eﬀectively induces antibody responses to GM2 [71, 72]. Both
approaches were tested in the phase III setting in E1694 and
EORTC 18961 against HDI and observation, respectively.
Neither failed to demonstrate any RFS/OS beneﬁt forvaccine
therapy—in EORTC 18961, the trial was actually terminated
as early evidence suggested that vaccination was ineﬀective
and potentially detrimental. When the ﬁnal results of
this trial were presented in 2010, the authors noted that
vaccination resulted in poorer DMFS and OS compared to
observation in a nonstatistically signiﬁcant fashion [73].
Administering GM2 with BCG or combining it with the
keyhole limpet hemocyanin (KLH) hapten and using a QS21
adjuvant is eﬀective in inducing an antibody response to
GM2. However, two large phase III trials (EORTC 18961 and
E1694)didnotdemonstrateasurvivalbeneﬁtwhenavaccine
using GM2-KLH with the saponin adjuvant QS21 was used
in an adjuvant setting [23, 73].
Seven large randomized trials of adjuvant allogeneic
melanoma cell-based vaccines have been conducted—none
of which have suggested any survival beneﬁt. An Australian
study using vaccinia viral lysates in high-risk patients follow-
ing deﬁnitive surgery found that immunotherapy resulted
was associated with a statistically nonsigniﬁcant increase in
RFS (50.9% treated group and 46.8% control group) [74].
A subsequent study evaluated LDI/melanoma lysate vaccine
combination (Arm 1) compared against standard HDI (Arm
2) in patients with resected stage III disease [75]. Authors
found that the LDI/vaccine combination was associated with
similar rates of OS and RFS at 32 months of followup as
HDI—61% (LDI/vaccine) versus 57% (HDI) for OS and
50% (LDI/vaccine) versus 48% (HDI) for RFS.
Morton’s studies with a polyvalent vaccine, known com-
mercially as Canvaxin, in stage III melanoma patients was
evaluated in a retrospective study [76], and it was suggested
that median and ﬁve-year OS were higher in vaccinated
patients than in nonvaccinated patients. However, when
subsequently in a phase III RCT for resected stage III/IV
melanoma compared against bCG vaccination, Canvaxin
failed to improve either DFS or OS with survival being
worse (5% in stage IV and 9% in stage III) likely secondary
to vaccine induced clinically signiﬁcant immunosuppression
[77].Journal of Skin Cancer 13
Table 4: Phase II/III studies of newer targeted agents.
Study
reference
No. of patients
eligible for
analysis
(followup)
Study design Primary
endpoint
Dose and
schedule—treatment
arm
ORR/OS PFS (mths) HR (95% CI)
BMS 008
[100] 155
Phase II,
open-label,
single arm
Dose ﬁnding Ipilimumab—
10mg/kg 47% (1yr) N/A N/A
BMS 022
[101] 217
Phase II,
randomized,
double blind
To evaluate the
eﬃcacy of three
dose levels of
ipilimumab
Ipilimumab—
10mg/kg 48% (1yr) N/A N/A
BMS 007
[102] 115
Phase II,
randomized,
double blind
To evaluate the
rate of grade 2 +
diarrhea
Ipilimumab—
10mg/kg 51% (1yr) N/A N/A
Medarex
MDX010-
20
[3]
676
Phase III,
randomized,
double blind
ORR,
subsequently
amended to OS
Ipilimumab—
3mg/kg
Ipi alone:
10.1 mths
(95% CI 8.0
to 13.8)
Ipi + GP-100:
10.0 mths
(95% CI 8.5
to 11.5)
GP-100
alone: 6.4
mths (95%
CI 5.5 to 8.7)
Ipi alone:
2.86 mths
(95% CI 2.76
to 3.02)
Ipi + GP-100:
2.76 mths
(95% CI 2.73
to 2.79)
GP-100
alone: 2.76
mths (95%
CI 2.73 to
2.83)
Ipi alone
(compared to
GP-100
alone):0.66
(95% CI
0.51-0.87)
Ipi + GP-100
(compared to
GP-100
alone):0.68
(95% CI
0.55-0.85)
BMS 024
[103] 502
Phase III,
randomized,
double blind
OS
Ipilimumab + DTIC:
Induction—IPI
10mg/kg + DTIC
(850mg/m2)q 3
weeks for 4 doses
Maintenance—IPI
10mg/kg + DTIC
(850mg/m2)q 1 2
weeks
Ipi + DTIC:
47.3% (1yr),
28.5% (2yr),
20.8% (3yr)
DTIC alone:
36.3% (1yr),
17.9% (2yr),
12.2% (3yr)
Ipi + DTIC:
2.8
DTIC alone:
2.6
Ipi + DTIC:
OS 0.72
PFS 0.76
BRIM 2
[104] 132 Phase II,
open label BORR
Vemurafenib
(PLX-4032) 960mg
twice daily orally
BORR:
52.3%
CR: 2.3%
PR: 50%
6.2 N/A
BRIM 3 [5] 675
Phase III,
randomized,
double blind
OS
Vemurafenib
(PLX-4032) 960mg
twice daily orally
PLX-4032:
84% (6mos)
DTIC alone:
64% (6mos)
PLX-4032:
5.3
DTIC alone:
1.6
Death 0.37
(95% CI 0.26
to 0.55)
Progression
0.26 (95% CI
0.20 to 0.33)
Key: N/A—not applicable.
3.7. Non-IFN-Based-Adjuvant Therapy: Radiation Therapy.
The optimal role for radiotherapy (RT) in the treatment
of melanoma is highly controversial. Once thought to be a
relatively radio-resistant tumor, in vitro studies of melanoma
cell lines have demonstrated widely diﬀering radiation
sensitivities within the same tumor. Available data suggests
that melanoma cells behave similarly to late-responding
tissues of mesenchymal or ectodermal origin that require
greater than standard doses per radiation fraction for most
eﬀective cell killing.
RT can be considered in the treatment of primary disease
when local surgical control cannot be obtained for cosmetic
or other reasons. If apparently adequate surgical margins
are obtained, RT may be used to reduce local recurrence
rates if other high-risk features are present. These include
melanomas with desmoplastic or neurotropic features and14 Journal of Skin Cancer
T4 lesions (particularly if ulcerated or associated with
satellitosis) as well as head and neck melanomas (especially
mucosal melanomas).
In the initial management of stage III disease, RT is rarely
indicated as surgical excision provides superior local control
as well as important diagnostic and prognostic information.
However, there is abundant evidence to suggest that cer-
tain clinicopathologic features strongly increase the risk of
locoregional relapse despite adequate surgery by as much as
30–50%. These include extracapsular lymph node extension,
involvement of 4 or more nodes, bulky disease (exceeding
3cm in size), cervical lymph node location, and recurrent
disease. However, retrospective phase II data evaluating the
use of RT in this instance is inconsistent. A prospective
multicenter phase III study, ANZMTG 01.02/TROG 02.01,
enrolled 250 patients at high risk of regional recurrence
in Australia, New Zealand, and the Netherlands. Follow-
ing lymphadenectomy, patients were randomized to either
observation or regional nodal basin RT (48Gy in 20
fractions). At a median follow-up time of 27 months, RT use
was associated with a statistically signiﬁcant improvement in
locoregionalcontrol(HR1.77,95%CI1.02–3.08,P = 0.041)
[78]. However a survival beneﬁt was not demonstrated, and
in fact, survival trends countervailed the relapse-free interval
beneﬁt such that it is now uncertain whether there is any role
for regional prophylactic RT in operable melanoma, except
when surgery has not been possible for clear margins. This
studysuggeststhatmelanomaisnotasradioresistantasonce
thought and advances several roles for RT in the adjuvant
treatment of high-risk stage III disease. Curiously, there was
no survival beneﬁt apparent from this intervention and a
trend toward adverse survival outcome in the group that
received RT compared to observation.
Several questions remain unanswered. Tumors with
extracapsular extension (ECE) were excluded from E1684—
one of only two trials to have demonstrated a survival
beneﬁt for HDI in the adjuvant setting. Whilst several other
trials have incorporated patients with ECE and other N3
features, the role of adjuvant HDI is less well deﬁned in this
setting. ECOG and the Radiation Therapy Oncology Group
(RTOG) planned a randomized trial to compare HDI plus
RT (30Gy in ﬁve fractions) to HDI alone for patients with
a high risk of locoregional recurrence risk. Unfortunately,
this was closed due to lack of accrual. At present, there is
no data evaluating the role of HDI in preventing systemic or
locoregional recurrence in patients with advanced regional
nodal disease, such as ECE, and standard therapy has not yet
been deﬁned for these patients.
3.8. Non-IFN-Based-Adjuvant Therapy: CTLA4 Blockade.
The anticytotoxic T-lymphocyte antigen-4 (anti-CTLA-4)
monoclonal antibody ipilimumab (MDX-010; Medarex
Inc/Bristol-Myers Squibb) is a fully humanized IgG1 mon-
oclonal antibody that blocks the CTLA-4 receptor that is
responsible for transmitting an inhibitory signal to T cells
to negatively regulate T-cell activation and proliferation—
inhibition results in enhanced T-cell activation and pro-
liferation.
Tremelmumabwasactuallyevaluatedbeforeipilimumab,
and despite encouraging results in phase II studies, it
produced negative results in the registration phase III trial
against dacarbazine that was closed early. Ipilimumab, how-
ever, has been hailed as a game changer in the treatment of
melanoma after demonstrating improved survival in a phase
III trial of patients with metastatic melanoma that compared
ipilimumab alone (at a dose of 3mg/kg), ipilimumab plus a
peptidevaccineagainstvaccineplusplacebo.Comparedwith
the peptide vaccine, ipilimumab showed a near doubling of
survivalratesat12months(46%versus25%)and24months
(24% versus 14%) and led to fast-track approval by the FDA
[3].
Recently, presented phase III data from a multicenter
study of 502 patients with previously untreated metastatic
disease that compared ipilimumab (at a dose of 10mg/kg)
with dacarbazine at 850mg/m2 to placebo with dacarbazine
demonstrated an overall OS that was durable and sustained
at3years[4].WhilstCTLA-4blockaderesultsinaplethoraof
immune adverse reactions including potentially fatal colitis,
the sustained overall response in 20.8% of patients at 3 years
provides an impetus to investigate the use of this agent in the
adjuvant setting.
Clinical trials are underway to assess the potential for
ipilimumabintheadjuvantsettingagainstHDIintheUnited
States (E1609) and against placebo in Europe (EORTC
18071). The EORTC 18071 trial has completed accrual, and
results are expected in 2013-2014.
3.9. Future Questions/Conclusion. The recent advances in
melanoma immunotherapy and molecular therapy directed
against the activating mutation of BRAF have reenergized
a ﬁeld that now has many promising agents for which the
beneﬁts in combination with one another are a challenge
to assess. Indeed, the prospect of testing combinations in
relation to conventional endpoints of OS are daunting,
and the adoption of intermediate clinical and laboratory
biomarker endpoints is a critical need.
TheresultsoftheUSintergroupstudyE1697suggestthat
the beneﬁt of IFN therapy requires more lengthy treatment
than just the induction phase of the HDI regimen. The ques-
tion of which subgroups of patients are most likely to derive
beneﬁts from IFN therapy is among the most pressing needs,
since treatment of only the ∼30% of patients who derive
beneﬁt would treble the therapeutic index of this agent.
Previous intergroup studies (E1684, E1690, E1694, EORTC
18952, and EORTC 18991) have suggested that the beneﬁt of
IFN is restricted to subpopulations of patients that may be
identiﬁed by the capacity to develop autoimmunity, or the
pathological appearance of the primary (ulcerated primaries
and/or microscopic node-positive disease). These bases of
focusing therapy are being investigated in current trials
such as E1697 and E1609 in which the immune responses
of patients are being evaluated, as well as the prospective
EORTCtrial18081thatwilltestthebeneﬁtof2yearsofpegy-
latedIFNcomparedtoobservationinpatientswithulcerated
stage II primary melanomas ≥1mm. The identiﬁcation of
the biomarkers of subpopulations of patients that are moreJournal of Skin Cancer 15
responsive will provide further insights into the mechanisms
of interferon antitumor activity.
The exciting long-term survival beneﬁts seen in patients
withmetastaticmelanomatreatedwithCTLA-blockadether-
apy have raised expectations that this therapy may have even
greater beneﬁts in the adjuvant setting. Multiple intergroup
and other trials are investigating the role of ipilimumab
in this setting including ECOG 1609 (ipilimumab versus
HDI after complete resection of high-risk Stage III/IV
melanoma), and EORTC 18071 (ipilimumab versus placebo
aftercompleteresectionofhigh-riskstageIIImelanoma)and
these results are eagerly awaited.
Given the low rate of response and high cost of treatment
with biologics including ipilimumab and IFN, prognos-
tic biomarkers that may predict therapeutic response to
immunotherapiesremainanareaofactiveongoinginvestiga-
tion. Unpublished data from the MDX010–20 study revealed
that absolute lymphocyte counts (ALC) drawn whilst on
treatment appear to increase in a dose-dependent fashion
with ipilimumab therapy—an eﬀect that was observed in
both the ipilimumab/vaccine and ipilimumab monother-
apy arms. High-baseline ALCs were associated with an
improved outcome, and changes in the ALC appeared to
correlate with overall survival beneﬁt. Such retrospective
analyses, however, need to be interpreted cautiously; studies
without a negative control arm can at best estimate the
prognostic utility of a biomarker, for example, predict OS.
Optimal biomarkers that predict treatment eﬀect need to
be prospectively evaluated in studies with control arms.
In metastatic disease, Hamid et al. [79] have reported the
improved outcome of ipilimumab therapy among patients
with elevated tumor inﬁltrating lymphocyte counts (TIL)
andelevatedTregandIDOlevelsatpretreatmentbiopsy. The
neoadjuvant setting, where there is access to tumor tissue
both before and after therapy, provides an ideal opportunity
to identify immunologic and histologic correlates of tumor
response. Data from an existing neoadjuvant study in which
patients received ipilimumab preoperatively followed by
lymphadenectomy, and 2 additional doses of maintenance
ipilimumab showed a signiﬁcant increase in the frequency of
circulating CD4 +CD25hi + Foxp3 + regulatory T cells [80],
a ﬁnding independently conﬁrmed by investigators from the
Moﬃt Cancer Center using samples derived from patients
treated with ipilimumab on an adjuvant trial [81]. Further
analysis comparing baseline and 6-week tumor samples is
ongoing.
With exciting results demonstrated in the registration
study against dacarbazine in metastatic melanoma, the use
of oncogenic BRAF inhibitors such as vemurafenib in the
adjuvant setting has been raised. However, the signiﬁcant
progression-free and overall survival beneﬁt observed was
temperedbytherealizationthatresistanceisrapidlyacquired
within several months of treatment. Concurrent inhibition
of downstream targets of the MAP kinase signaling pathway
such as MEK could be a potential solution to this problem.
The year 2011 will likely be remembered as one in
which treatments for melanoma dominated news broad-
casts all over the world. The optimal combination and
sequence of these active agents to derive lasting disease and
progression-free survival and maybe even elicit a cure will
be the subject of intense investigation in the upcoming
years. This will likely be achieved by rationally combining
immunotherapy with other forms of targeted and cytotoxic
chemotherapies. It is hoped that the impetus provided by
recent advances will translate into objective beneﬁts for our
patients.
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